Amicus Therapeutics, Inc. – NASDAQ:FOLD

Add to watchlist

$7.25

-2.38

-24.71%

Market closed

Open in 23 minutes

-7.49%

month

-7.49%

quarter

-33.26%

year

Market Cap	2.90B
Enterprise value	3.54B

P/E	-13.49
EV/Sales	10.75
EV/EBITDA	-17.74
Price/Sales	9.83
Price/Book	26.31
PEG ratio	-1.24
EPS	-0.50

Revenue	423.48M
EBITDA	-74.58M
Income	-147.07M
Revenue Q/Q	27.97%
Revenue Y/Y	25.74%

Profit margin	-71.85%
Oper. margin	-62.09%
Gross margin	88.28%
EBIT margin	-62.09%
EBITDA margin	-17.61%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Amicus Therapeutics Stock Forecast

M Q Y

Last Year

$15

Potential upside: 106.89%

Analysts Price target
Financials & Ratios estimates

Amicus Therapeutics, Inc. (NASDAQ:FOLD): Profit margin
Jun 2023	94.50M	-43.23M	-45.75%
Sep 2023	103.50M	-21.57M	-20.85%
Dec 2023	115.08M	-33.84M	-29.41%
Mar 2024	110.40M	-48.41M	-43.86%

Amicus Therapeutics, Inc. (NASDAQ:FOLD): Debt to assets
Jun 2023	730093000	618.51M	84.72%
Sep 2023	764084000	630.84M	82.56%
Dec 2023	777880000	617.70M	79.41%
Mar 2024	721789000	591.09M	81.89%

Amicus Therapeutics, Inc. (NASDAQ:FOLD): Cash Flow
Jun 2023	-16.13M	50.00M	23.67M
Sep 2023	-38.34M	35.76M	37.61M
Dec 2023	3.45M	-23.95M	8.21M
Mar 2024	-29.69M	7.53M	-13.30M

Amicus Therapeutics alternative data

Amicus Therapeutics
Employees

Amicus Therapeutics, Inc. (NASDAQ:FOLD): Employee count
Aug 2023	484
Sep 2023	484
Oct 2023	484
Nov 2023	484
Dec 2023	484
Jan 2024	484
Feb 2024	484
Mar 2024	517
Apr 2024	517
May 2024	517
Jun 2024	517
Jul 2024	517

Amicus Therapeutics
Hedge Funds Holdings Q1 2022

100.00% 0.00%

of FOLD is owned by hedge funds

205 -13

hedge funds hold FOLD stock

300.20M -1.08M

shares is hold by hedge funds

FOLD hedge funds holdings changes

Amicus Therapeutics
Insider Trading

Amicus Therapeutics, Inc. (NASDAQ:FOLD): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	206602
Feb 2024	0	117655
Mar 2024	0	60014
Apr 2024	0	7500
May 2024	0	7500
Jun 2024	0	7500
Jul 2024	0	7500
Aug 2024	0	7500
Sep 2024	0	7500
Oct 2024	0	7500
Nov 2024	0	15401
Dec 2024	0	7500

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	2 Dec 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Common Stock	7,500	$8.61	$64,575
Sale	2 Dec 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Common Stock	7,500	$10.02	$75,128
Option	2 Dec 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Stock Options (right to buy)	7,500	$8.61	$64,575
Option	6 Nov 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Common Stock	7,901	$12.28	$97,024
Sale	6 Nov 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Common Stock	7,901	$12.51	$98,802
Option	6 Nov 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Stock Options (right to buy)	7,901	$12.28	$97,024
Option	1 Nov 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Common Stock	7,500	$8.61	$64,575
Sale	1 Nov 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Common Stock	7,500	$11.46	$85,958
Option	1 Nov 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Stock Options (right to buy)	7,500	$8.61	$64,575
Option	1 Oct 2024	CAMPBELL BRADLEY L director, officer: President and CEO director, officer: President an..	Common Stock	7,500	$8.61	$64,575

FOLD insider trading transactions

Amicus Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 8 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript

FOLD earnings call transcripts

Amicus Therapeutics
Executives

Insider	Age	Compensation
Mr. John F. Crowley (1967) Chairman & Chief Executive Officer	58	$2,060,000
Mr. Bradley L. Campbell M.B.A. (1976) Pres, Chief Operating Officer & Director	49	$918,360
Ms. Daphne E. Quimi CPA (1966) Chief Financial Officer	59	$714,950
Ms. Ellen S. Rosenberg (1963) Chief Legal Officer & Corporation Sec.	62	$672,090

Amicus Therapeutics
Latest News

Friday, 27 December 2024
13:33	Amicus Therapeutics: Cheap Heading Into 2025	seekingalpha.com
Monday, 23 December 2024
15:43	NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It	globenewswire.com
12:46	HALO or FOLD: Which Is the Better Value Stock Right Now?	zacks.com
Wednesday, 18 December 2024
13:09	NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act	globenewswire.com
Friday, 13 December 2024
15:28	Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension	globenewswire.com
14:10	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?	benzinga.com
10:50	Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?	zacks.com
Monday, 9 December 2024
06:49	Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?	zacks.com
Thursday, 5 December 2024
12:41	HALO vs. FOLD: Which Stock Is the Better Value Option?	zacks.com
Tuesday, 3 December 2024
13:14	NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial	globenewswire.com
Tuesday, 19 November 2024
12:40	HALO vs. FOLD: Which Stock Should Value Investors Buy Now?	zacks.com
Tuesday, 12 November 2024
19:04	NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights	globenewswire.com
Thursday, 7 November 2024
11:40	Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated	zacks.com
10:55	Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock	zacks.com
Wednesday, 6 November 2024
21:30	Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings	zacks.com
12:54	Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript	seekingalpha.com
09:25	Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates	zacks.com
Monday, 4 November 2024
10:55	Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know	zacks.com
Friday, 1 November 2024
07:00	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024	globenewswire.com
Wednesday, 30 October 2024
11:06	Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth	zacks.com
Monday, 28 October 2024
07:00	Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024	globenewswire.com
Thursday, 24 October 2024
11:16	Best Momentum Stocks to Buy for October 24th	zacks.com
10:11	5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright	zacks.com
08:31	New Strong Buy Stocks for October 24th	zacks.com
Monday, 21 October 2024
16:18	American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas	globenewswire.com
16:17	3 Attractive Biotechs With Recent Positives	seekingalpha.com
10:55	Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term	zacks.com
Friday, 18 October 2024
15:47	Amicus: Teva Settlement Clears Revenue Path Forward For Galafold	seekingalpha.com
13:21	Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?	zacks.com
11:36	FOLD Stock Rises on Settling Galafold Patent Dispute With Teva	zacks.com

Ideas & Opinions

Seeking Alpha 1 Aug 2025

Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
Seeking Alpha 12 Jun 2025

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma
Seeking Alpha 13 Jan 2025

3 Oversold Biotech Names
Seeking Alpha 27 Dec 2024

Amicus Therapeutics: Cheap Heading Into 2025
Seeking Alpha 2 Jun 2024

3 Biotech Names Under $10 I Own
Seeking Alpha 20 May 2024

Amicus Therapeutics: Too Cheap At Under $10 A Share
Seeking Alpha 31 Oct 2023

Amicus Therapeutics: The Right Play Now
Seeking Alpha 29 Sep 2023

Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter
Seeking Alpha 25 Aug 2023

Amicus Therapeutics: U.K. Approval Expands Global Reach
Seeking Alpha 22 May 2023

Amicus Therapeutics: Finally The FDA Inspection Is Done, Time To Be Positive

Frequently Asked Questions (FAQ)

What's the price of Amicus Therapeutics stock today?

One share of Amicus Therapeutics stock can currently be purchased for approximately $7.25.
When is Amicus Therapeutics's next earnings date?

Unfortunately, Amicus Therapeutics's (FOLD) next earnings date is currently unknown.
Does Amicus Therapeutics pay dividends?

No, Amicus Therapeutics does not pay dividends.
How much money does Amicus Therapeutics make?

Amicus Therapeutics has a market capitalization of 2.90B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.3% to 399.36M US dollars.
What is Amicus Therapeutics's stock symbol?

Amicus Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FOLD".
What is Amicus Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Amicus Therapeutics?

Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Amicus Therapeutics's key executives?
Amicus Therapeutics's management team includes the following people:
- Mr. John F. Crowley Chairman & Chief Executive Officer(age: 58, pay: $2,060,000)
- Mr. Bradley L. Campbell M.B.A. Pres, Chief Operating Officer & Director(age: 49, pay: $918,360)
- Ms. Daphne E. Quimi CPA Chief Financial Officer(age: 59, pay: $714,950)
- Ms. Ellen S. Rosenberg Chief Legal Officer & Corporation Sec.(age: 62, pay: $672,090)
How many employees does Amicus Therapeutics have?

As Jul 2024, Amicus Therapeutics employs 517 workers.
When Amicus Therapeutics went public?

Amicus Therapeutics, Inc. is publicly traded company for more then 18 years since IPO on 31 May 2007.
What is Amicus Therapeutics's official website?

The official website for Amicus Therapeutics is amicusrx.com.
Where are Amicus Therapeutics's headquarters?

Amicus Therapeutics is headquartered at 3675 Market Street, Philadelphia, PA.
How can i contact Amicus Therapeutics?

Amicus Therapeutics's mailing address is 3675 Market Street, Philadelphia, PA and company can be reached via phone at 215 921 7600.
What is Amicus Therapeutics stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Amicus Therapeutics in the last 12 months, the avarage price target is $15. The average price target represents a 106.89% change from the last price of $7.25.

Amicus Therapeutics, Inc.

amicusrx.com

Exchange:

NASDAQ

Full time employees:

500

Industry:

Biotechnology

Sector:

Healthcare

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

215 921 7600

3675 Market Street
Philadelphia, PA 19104

CIK: 0001178879
ISIN: US03152W1099
CUSIP: 03152W109